ReviewNature reviews. Endocrinology2012
Diagnosis and management of parathyroid cancer.
Review in Nature reviews. Endocrinology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 132 citations in OpenAlex.
- Rebound hypercalcemia after denosumab cessation during follow-up after surgical treatment for parathyroid carcinoma: case report and literature review.Archives of endocrinology and metabolism · 2024Pooled it
- Case Report and Systematic Review: Sarcomatoid Parathyroid Carcinoma-A Rare, Highly Malignant Subtype.Frontiers in endocrinology · 2021Pooled it
- Current concepts in parathyroid carcinoma: a single Centre experience.BMC endocrine disorders · 2019Trial
- PTH-to-tumor-volume ratio as a potential exploratory marker in parathyroid carcinoma: a retrospective cohort study.Updates in surgery · 2026Article
- Comparing deep-learning, radiomics, and fusion models for parathyroid tumor classification using ultrasound: a multicenter retrospective study.Quantitative imaging in medicine and surgery · 2026Article
- Article
- Potential higher malignancy of nonfunctional parathyroid carcinoma: a case series study.Gland surgery · 2025Article
- Diagnostic and Therapeutic Challenges in Parathyroid Cancers: 15 Years' Experience in a Tertiary Center and an Endocrine Surgery Referral Hospital.Journal of clinical medicine · 2025Article
- Metastatic Parathyroid Carcinoma in a Young Adult With Recurrent Hypercalcemia and Acute Necrotizing Pancreatitis.Cureus · 2025Article
- An explainable radiomics-based machine learning model for preoperative differentiation of parathyroid carcinoma and atypical tumors on ultrasound: a retrospective diagnostic study.Frontiers in endocrinology · 2025Article
- A retrospective study on a nomogram combining clinical and ultrasound parameters for differentiating solitary parathyroid adenoma from carcinoma or atypical tumors.Frontiers in endocrinology · 2025Article
- Cohort review of patients with parathyroid cancer in End Stage Renal Disease (ESRD).Langenbeck's archives of surgery · 2024Review
- Risk Factors of Distant Metastatic Parathyroid Carcinoma and Insights into Therapeutic Perspectives.Annals of surgical oncology · 2024Observational
- Imaging Recommendations for Diagnosis and Management of Primary Parathyroid Pathologies: A Comprehensive Review.Cancers · 2024Review
- A case report of mediastinal parathyroid carcinoma in a chronic kidney disease patient: Addressing management conundrum.SAGE open medical case reports · 2024Article
- Diagnostic dilemma in a rare case of nonfunctional parathyroid carcinoma at a referral facility in Northern Tanzania.Clinical case reports · 2023Article
- Mediastinal parathyroid carcinoma: a case report and review of the literature.BMC endocrine disorders · 2023Review
- Overexpression of HSF2 binding protein suppresses endoplasmic reticulum stress via regulating subcellular localization of CDC73 in hepatocytes.Cell & bioscience · 2023Article
- Evaluation of factors predicting postoperative recurrence and metastasis of parathyroid cancer: a single-center study.World journal of surgical oncology · 2023Article
- Giant functional parathyroid carcinoma: a case report and literature review.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parathyroid cancer is rare, but often fatal, as preoperative identification of malignancy against the backdrop of benign parathyroid disease is challenging. Advanced genetic, laboratory and imaging techniques can help to identify parathyroid cancer. In patients with clinically suspected parathyroid cancer, malignancy of any individual lesion is established by three criteria: demonstration of metastasis, specific ultrasonographic features, and a ratio >1 for the results of third-generation:second-generation parathyroid hormone assays. Positive findings for all three criteria dictate an oncological surgical approach, as appropriate radical surgery can achieve a cure. Mutation screening pinpoints associated conditions and asymptomatic carriers. Molecular profiling of tumour cells can identify high-risk features, such as differential expression of specific micro-RNAs and proteins, and germ line mutations in CDC73, but is unsuitable for preoperative assessment owing to the potential risks associated with biopsy. A validated, histopathology-based prognostic classification can identify patients in need of close follow-up and adjuvant therapy, and should prove valuable to stratify clinical trial cohorts: low-risk patients rarely die from parathyroid cancer, even on long-term follow-up, whereas 5-year mortality in high-risk patients is around 50%. This insight has improved the approach to parathyroid cancer by enabling risk-adapted surgery and follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.